Published in Cancer Res on February 15, 2004
Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J (2005) 2.03
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
ABCG2 transporter identifies a population of clonogenic human limbal epithelial cells. Stem Cells (2005) 1.95
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol (2012) 1.65
EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer (2012) 1.63
The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome. Dev Biol (2006) 1.54
Trafficking of heme and porphyrins in metazoa. Chem Rev (2009) 1.48
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer (2011) 1.30
Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res (2008) 1.26
Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol (2011) 1.21
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther (2007) 1.18
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther (2009) 1.14
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal (2009) 1.11
Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo. J Med Chem (2009) 1.07
The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol (2011) 1.06
ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem (2010) 1.05
Botryllamides: natural product inhibitors of ABCG2. ACS Chem Biol (2009) 1.05
Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells. Drug Metab Dispos (2011) 1.05
Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J (2005) 1.03
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther (2012) 1.03
Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. PLoS One (2011) 1.01
Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods (2010) 0.99
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98
Mechanisms of resistance to photodynamic therapy. Curr Med Chem (2011) 0.96
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep (2009) 0.96
βArrestin-1 and Mcl-1 modulate self-renewal growth of cancer stem-like side-population cells in non-small cell lung cancer. PLoS One (2013) 0.96
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol Pharmacol (2007) 0.94
A new ABC half-transporter in Leishmania major is involved in resistance to antimony. Antimicrob Agents Chemother (2013) 0.89
Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos (2013) 0.88
Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters. Anal Biochem (2013) 0.88
Arginine 383 is a crucial residue in ABCG2 biogenesis. Biochim Biophys Acta (2009) 0.88
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res (2015) 0.87
Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol (2012) 0.86
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy. Sci Rep (2015) 0.84
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol (2009) 0.84
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem Pharmacol (2012) 0.84
Lamellarin O, a pyrrole alkaloid from an Australian marine sponge, Ianthella sp., reverses BCRP mediated drug resistance in cancer cells. Mar Drugs (2014) 0.84
Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm (2010) 0.84
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One (2012) 0.82
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemother Pharmacol (2009) 0.82
Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos. Mol Reprod Dev (2014) 0.81
Chlorin e6 - polyvinylpyrrolidone mediated photosensitization is effective against human non-small cell lung carcinoma compared to small cell lung carcinoma xenografts. BMC Pharmacol (2007) 0.81
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nucl Med Biol (2010) 0.81
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists. Br J Pharmacol (2013) 0.81
Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid. J Med Chem (2014) 0.80
The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing. PLoS One (2014) 0.80
A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. J Cancer Res Clin Oncol (2014) 0.80
Assessment of drug transporter function using fluorescent cell imaging. Curr Protoc Toxicol (2013) 0.80
Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach. Mol Pharm (2014) 0.79
Structure-activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J (2009) 0.79
Design, synthesis, and biological evaluation of (S)-valine thiazole-derived cyclic and noncyclic peptidomimetic oligomers as modulators of human P-glycoprotein (ABCB1). Chembiochem (2013) 0.78
Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter. Curr Drug Metab (2015) 0.78
New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity. Drug Des Devel Ther (2013) 0.78
Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells. Cancer Biol Ther (2013) 0.75
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators. ACS Med Chem Lett (2013) 0.75
The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant. Mol Cell Biochem (2008) 0.75
Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Lett (2017) 0.75
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev (2007) 2.31
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep (2013) 2.24
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res (2007) 2.15
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther (2007) 2.11
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther (2002) 1.88
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist (2008) 1.85
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res (2002) 1.82
ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther (2005) 1.79
ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol (2008) 1.65
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res (2003) 1.62
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol (2008) 1.58
Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res (2005) 1.55
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. J Natl Cancer Inst (2011) 1.50
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther (2007) 1.47
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res (2011) 1.46
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry (2006) 1.45
Cardiac involvement with lymphoma: a review of the literature. Clin Lymphoma Myeloma (2008) 1.43
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos (2010) 1.41
Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res (2009) 1.38
Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat (2012) 1.35
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res (2011) 1.34
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res (2008) 1.34
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther (2010) 1.34
Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res (2005) 1.33
Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug. J Biol Chem (2004) 1.31
Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol (2005) 1.30
Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry (2004) 1.29
Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells (2006) 1.29
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle (2005) 1.29
A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen (2006) 1.26
Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol (2006) 1.26
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat (2012) 1.23
A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res (2004) 1.23
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res (2007) 1.20
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
The controversial role of ABC transporters in clinical oncology. Essays Biochem (2011) 1.18
New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther (2007) 1.18
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res (2006) 1.18
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res (2009) 1.17
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res (2009) 1.15
Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochim Biophys Acta (2002) 1.14
Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett (2005) 1.14
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist (2008) 1.14
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther (2009) 1.14
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol (2008) 1.12
Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res (2012) 1.10
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res (2012) 1.09
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs (2007) 1.09
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica (2009) 1.08
ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs (2002) 1.07
Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm (2011) 1.06
The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol (2011) 1.06
ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem (2010) 1.05
Botryllamides: natural product inhibitors of ABCG2. ACS Chem Biol (2009) 1.05
Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J (2007) 1.04
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res (2010) 1.04
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood (2002) 1.03
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Mol Cancer Ther (2007) 1.02
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol (2009) 1.01
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res (2005) 1.01
Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res (2006) 1.01
Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods (2010) 0.99
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther (2006) 0.99
In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity. Mol Cancer Ther (2004) 0.99
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene (2002) 0.98
Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol Cancer Ther (2007) 0.97
Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents. J Med Chem (2002) 0.97
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep (2009) 0.96
Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry (2010) 0.96
Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study. J Mol Graph Model (2006) 0.95
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle (2011) 0.95
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res (2003) 0.95
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res (2010) 0.94
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol Pharmacol (2007) 0.94
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood (2013) 0.92
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biol Rep (2010) 0.92